The mean versus the gene: will national healthcare systems ever adopt personalised medicine?

By John F P Bridges While outcomes for any given treatment differ significantly among patients, national healthcare systems continue to take a top down population perspective in reviewing not only epidemiologic data but to evaluating the effectiveness and cost-effectiveness of new medicines. This top down approach, coupled with a growing need for cost containment, has…

Details

ISMPP: Former Merck CEO outlines three ways pharma companies can regain lost prestige

By David Woods ([email protected]) While the Golden Age of the pharmaceutical industry is over, and its reputation similar to that of the tobacco and oil industries, there is hope at hand – according to former Merck CEO Roy Vagelos. In a keynote address to the third annual meeting of the International Society for Medical Publication…

Details